Ching-Hon Pui.

The final risk status was established based on the known level of minimal residual disease. Any patient with a level of minimal residual disease of 1 percent or more in the bone marrow aspirate on time 19 of remission induction or 0.10 to 0.99 percent minimal residual disease after completion of 6 weeks of induction therapy was considered to have got standard-risk ALL. A level of minimal residual disease of 1 percent or more after completion of induction therapy indicated high-risk ALL.‘Next Generation Sequencing opens a fresh dimension in biomarker study and will allow a finer grained, unbiased look at some of the genomic mechanisms behind prostate disease, thus providing the opportunity for the discovery of new prognostic biomarkers, some of which may be targets for therapeutic intervention and treatment monitoring also.’ Dr. Shiv Srivastava; CPDR Co-director, Scientific Director, and Professor of Medical procedures at USU added: ‘Our work to date with Genomatix has been very productive.